All In Biotech

Drug Trial Radar · NCT03043872

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 987 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

987

Actual

Start

Mar 27, 2017

Primary completion

Jan 27, 2020

Study completion Dec 31, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer

Conditions

  • Small Cell Lung Carcinoma Extensive Disease

Interventions

  • DurvalumabDrug

    IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.

  • TremelimumabDrug

    IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.

  • CarboplatinDrug

    up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

  • CisplatinDrug

    up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

  • EtoposideDrug

    up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
  2. OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
  3. OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
  4. OS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EPTime frame: From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).

Locations

207 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Rogers, Arkansas

  • Research Site

    Santa Monica, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Athens, Georgia

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Muncie, Indiana

  • Research Site

    Leawood, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Paducah, Kentucky

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Mineola, New York

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Harrisburg, Pennsylvania

  • Research Site

    Sioux Falls, South Dakota

  • Research Site

    Nashville, Tennessee

  • Research Site

    Kennewick, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Linz, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Barretos, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Passo Fundo, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Panagyurishte, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

Showing 40 of 207 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.